Document is current

Any future updates will be listed below

Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients

Crossref DOI link: https://doi.org/10.1007/s40744-025-00799-x

Published Online: 2025-11-20

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark